Adverum Biotechnologies, Inc. – NASDAQ:ADVM
Adverum Biotechnologies stock price today
$2.84
-1.96
-40.83%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 17 hours
Adverum Biotechnologies stock price monthly change
-39.32%
month
Adverum Biotechnologies stock price quarterly change
-39.32%
quarter
Adverum Biotechnologies stock price yearly change
+537.45%
year
Adverum Biotechnologies key metrics
Market Cap | 97.56M |
Enterprise value | 112.80M |
P/E | -0.49 |
EV/Sales | N/A |
EV/EBITDA | -0.49 |
Price/Sales | N/A |
Price/Book | 0.41 |
PEG ratio | -0.05 |
EPS | -10.23 |
Revenue | N/A |
EBITDA | -116.64M |
Income | -112.89M |
Revenue Q/Q | -100% |
Revenue Y/Y | -200% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAdverum Biotechnologies stock price history
Adverum Biotechnologies stock forecast
Adverum Biotechnologies financial statements
Average Price Target
$17.5
Potential upside: 516.19%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 0 | -31.51M | |
|---|---|---|---|
| Sep 2023 | 0 | -32.88M | |
| Dec 2023 | -3.6M | -23.71M | 658.72% |
| Mar 2024 | 0 | -24.78M |
| Jun 2023 | 241429000 | 110.27M | 45.68% |
|---|---|---|---|
| Sep 2023 | 196770000 | 94.05M | 47.8% |
| Dec 2023 | 173010000 | 89.54M | 51.75% |
| Mar 2024 | 267827999 | 85.54M | 31.94% |
| Jun 2023 | -23.24M | 67.02M | 8K |
|---|---|---|---|
| Sep 2023 | -23.91M | 18.19M | -105K |
| Dec 2023 | -21.40M | -9.87M | 242K |
| Mar 2024 | -23.24M | -22.02M | 119.88M |
Adverum Biotechnologies alternative data
| Aug 2023 | 123 |
|---|---|
| Sep 2023 | 123 |
| Oct 2023 | 123 |
| Nov 2023 | 123 |
| Dec 2023 | 123 |
| Jan 2024 | 123 |
| Feb 2024 | 123 |
| Mar 2024 | 121 |
| Apr 2024 | 121 |
| May 2024 | 121 |
| Jun 2024 | 121 |
| Jul 2024 | 121 |
Adverum Biotechnologies other data
39.88%
-17.72%
of ADVM is owned by hedge funds
34
-25
39.58M
-17.72M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2023 | 0 | 61898 |
| Jun 2023 | 100000 | 0 |
| Sep 2023 | 0 | 6201 |
| Feb 2024 | 230000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | LUPHER, JR. MARK L. director | Common Stock | 130,000 | $1.35 | $175,500 | ||
Purchase | SCOPA JAMES PAUL director | Common Stock | 100,000 | $1.35 | $135,000 | ||
Sale | SEYEDKAZEMI SETAREH officer: Chief Development Offi.. | Common Stock | 6,071 | $1.52 | $9,228 | ||
Sale | SEYEDKAZEMI SETAREH officer: Chief Development Offi.. | Common Stock | 130 | $1.55 | $201 | ||
Purchase | RUBINSTEIN LINDA M officer: Chief Financial Officer | Common Stock | 100,000 | $1.46 | $145,500 | ||
Sale | FISCHER LAURENT director, officer.. | Common Stock | 41,239 | $0.78 | $32,249 | ||
Sale | SOPARKAR PETER officer: Chief Operating Officer | Common Stock | 13,360 | $0.78 | $10,448 | ||
Sale | RILEY BRIGIT officer: Chief Scientific Officer | Common Stock | 7,299 | $0.78 | $5,708 | ||
Sale | BECKMAN RICHARD officer: Chief Medical Officer | Common Stock | 4,272 | $1.07 | $4,571 | ||
Sale | FISCHER LAURENT director, officer.. | Common Stock | 41,082 | $1.07 | $43,958 |
| Patent |
|---|
Grant Filling date: 23 Jan 2020 Issue date: 30 Aug 2022 |
Application Filling date: 20 Sep 2021 Issue date: 25 Aug 2022 |
Application Filling date: 20 Dec 2021 Issue date: 18 Aug 2022 |
Application Filling date: 29 Oct 2021 Issue date: 21 Jul 2022 |
Application Filling date: 3 Mar 2022 Issue date: 16 Jun 2022 |
Grant Filling date: 20 Aug 2020 Issue date: 7 Jun 2022 |
Grant Filling date: 18 May 2018 Issue date: 15 Feb 2022 |
Application Filling date: 5 May 2021 Issue date: 16 Dec 2021 |
Grant Filling date: 19 Oct 2017 Issue date: 7 Dec 2021 |
Grant Filling date: 2 Mar 2016 Issue date: 1 Jun 2021 |
| Quarter | Transcript |
|---|---|
| Q4 2020 1 Mar 2021 | Q4 2020 Earnings Call Transcript |
| Q2 2020 11 Aug 2020 | Q2 2020 Earnings Call Transcript |
| Q1 2020 29 May 2020 | Q1 2020 Earnings Call Transcript |
| Q4 2019 13 Mar 2020 | Q4 2019 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Laurent Fischer (1964) Pres, Chief Executive Officer, Interim CMO & Director | $922,920 |
4D Molecular Therapeutics: Another Gene Therapy Player With A Differentiated Profile
Regenxbio: Suprachoroidal Data May Impress
Regenxbio: Better Investment Case Than Adverum
Adverum Biotechnologies: An Uncertain Path Forward
Adverum Biotechnologies: One Adverse Event Too Many
Ocular Therapeutix: Good Medicine, High Competition
-
What's the price of Adverum Biotechnologies stock today?
One share of Adverum Biotechnologies stock can currently be purchased for approximately $2.84.
-
When is Adverum Biotechnologies's next earnings date?
Unfortunately, Adverum Biotechnologies's (ADVM) next earnings date is currently unknown.
-
Does Adverum Biotechnologies pay dividends?
No, Adverum Biotechnologies does not pay dividends.
-
How much money does Adverum Biotechnologies make?
Adverum Biotechnologies has a market capitalization of 97.56M.
-
What is Adverum Biotechnologies's stock symbol?
Adverum Biotechnologies, Inc. is traded on the NASDAQ under the ticker symbol "ADVM".
-
What is Adverum Biotechnologies's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Adverum Biotechnologies?
Shares of Adverum Biotechnologies can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Adverum Biotechnologies's key executives?
Adverum Biotechnologies's management team includes the following people:
- Dr. Laurent Fischer Pres, Chief Executive Officer, Interim CMO & Director(age: 61, pay: $922,920)
-
How many employees does Adverum Biotechnologies have?
As Jul 2024, Adverum Biotechnologies employs 121 workers.
-
When Adverum Biotechnologies went public?
Adverum Biotechnologies, Inc. is publicly traded company for more then 11 years since IPO on 31 Jul 2014.
-
What is Adverum Biotechnologies's official website?
The official website for Adverum Biotechnologies is adverum.com.
-
Where are Adverum Biotechnologies's headquarters?
Adverum Biotechnologies is headquartered at 800 Saginaw Drive, Redwood City, CA.
-
How can i contact Adverum Biotechnologies?
Adverum Biotechnologies's mailing address is 800 Saginaw Drive, Redwood City, CA and company can be reached via phone at +65 06569323.
-
What is Adverum Biotechnologies stock forecast & price target?
Based on 3 Wall Street analysts` predicted price targets for Adverum Biotechnologies in the last 12 months, the avarage price target is $17.5. The average price target represents a 516.19% change from the last price of $2.84.
Adverum Biotechnologies company profile:
Adverum Biotechnologies, Inc.
adverum.comExchange:
NASDAQ
Full time employees:
121
Industry:
Biotechnology
Sector:
Healthcare
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
800 Saginaw Drive
Redwood City, CA 94063
Redwood City, CA 94063
CIK: 0001501756
ISIN: US00773U1088
CUSIP: 00773U108
